CuriRx, Inc., a CRO and product development organization, launched its new CuriLytics platform with High-Resolution Chemistry Manufacturing and Control (CMC) analytical services. Leveraging its high-resolution Orbitrap mass spectrometry instrumentation, the CuriLytics platform provides support to developers of complex biotherapeutics.
 
The platform aims to address the challenges characterizing very complex molecules such as, recombinant proteins, monoclonal antibodies (mAb), bispecific antibodies, vaccines, antibody drug conjugates (ADCs), oligonucleotides, and gene therapy products (e.g., AAV’s)
 
Using high-resolution mass spectrometry and various orthogonal characterization methods, CuriLytics is designed to provide greater insight in characterization and improved understanding of biotherapeutics. CuriLytics identifies quality attributes of protein candidates at the individual residue level, offering a detailed understanding of how changes in process or production affect a drug product.
 
CuriRx CEO Indu Javeri remarked, “Analytical methods to characterize and assess highly complex biotherapeutics have struggled to keep up, putting many drug development programs at risk. The CuriLytics™ platform is designed to provide confidence to biotherapeutic developers from discovery to regulatory approval.”